"Designing Growth Strategies is in our DNA"
Testicular cancer refers to the type of cancer that occurs in the testes or testicles, an important organ in the male reproductive system, responsible for the production of male sex hormones and sperms for the purpose of reproduction. When considered along with other forms of cancers, testicular cancer is relatively rarer, but the most common form of cancer in males of ages 15-35. Treatment of testicular cancer is highly probable, even when cancer has spread beyond the testicles. The symptoms of testicular cancer include a lump in either of the testes, heaviness in the scrotum, sudden accumulation of fluid in the scrotum, dull ache in groin or abdomen, discomfort or pain in the testes or scrotum and back pain.
The individuals at most risks of being diagnosed with testicular cancer include those with an undescended testicle, presence of familial history, abnormal testes development, males in younger age groups and especially white men in terms of race. Treatment of testicular cancer includes surgical procedures, chemotherapy, and radiation therapy. Due to the rising prevalence of almost all forms of cancer, it is anticipated that the testicular cancer drugs market will exhibit positive growth, due to its strong occurrence in men of younger age groups.
To gain extensive insights into the market, Request for Customization
The global testicular cancer drugs market is anticipated to grow, owing to a number of factors such as increased prevalence of testicular cancers, increasing advancements in treatment of testicular cancers, good prognosis rates in early detection, increasing demand for preventive care leading to early diagnosis, highly curable nature of the disease and increasing awareness of testicular cancer. According to the American Society for Clinical Oncology (ASCO), it was estimated that in the U.S., in 2017, 9,310 men were diagnosed with testicular cancer and the average age of diagnosis was 33 and testicular cancer was also the most common form of cancer in the age group of 15-35. These trends combined with the other factors are expected to positively drive the market growth.
The factors limiting the growth of global testicular cancer drugs market include the associated side effects of the treatment options and lack of diagnosis in earlier stages of testicular cancer.
Some of the major companies that are present in the global testicular cancer drugs market are Bristol-Myers Squibb Company, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, Pfizer Inc., H. Lundbeck A/S, Ziopharm Oncology, Inc, and others.
By Type of Cancer
· Classical (Typical)
· Embryonal Carcinoma
· Yolk Sac Carcinoma
By Distribution Channel
· Hospital Pharmacies
· Retail Pharmacies
· Online Pharmacies
· North America (USA and Canada)
· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
· Latin America (Brazil, Mexico and Rest of Latin America)
· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Among the segmentation, bleomycin- etoposide-paclitaxel (BEP) in the drug segment is projected to hold a considerable share of the global testicular cancer drugs market due to higher adoption of this combination of drugs for the effective treatment of testicular cancer.
North America accounts for the largest share in the global market due to the increasing prevalence of testicular cancer, established healthcare system, high medical expenditure, access to advanced treatment options, demand for preventive care by diagnostic examinations and greater awareness of testicular cancer. The Asia Pacific is the fastest emerging market due to increasing incidences of testicular cancer, large population pools, the younger male population in certain regions, increasing awareness, increasing access to advanced treatment options and increasing healthcare expenditure due to greater disposable incomes.
Key Industry Developments
As of August 2018, a clinical trial is in Phase II which is testing whether the Cyclin-Dependent Kinase Inhibitor PD 0332991 may stop the growth of the tumor cells of several types of cancers including testicular cancer by blocking some of the enzymes needed for the cell growth of these cancerous cells. The trial is currently being conducted by the Abramson Cancer Center of the University of Pennsylvania.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry